Ipsen Announces Encouraging Phase II Results for IPN10200 in Treating Glabellar Lines, Demonstrating Sustained Effectiveness
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 22 2025
0mins
Source: NASDAQ.COM
Phase II LANTIC Trial Results: Ipsen's IPN10200 showed significant improvement in treating glabellar lines at Week 4 compared to placebo, with continued superior results at Week 36 versus Dysport.
Future Developments: Data from the trial will be presented at a scientific conference in 2026, and Phase III activities have begun, while Phase II continues for other therapeutic uses like spasticity and migraines.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
